Bristol’s “Underperforming” Mead Johnson, OTCs Could Be Shown The Door
This article was originally published in The Tan Sheet
Executive Summary
Mead Johnson's sluggish sales, coupled with the low margins of nutritionals relative to pharmaceuticals, could make the Bristol-Myers Squibb unit ripe for divestiture or spin-off as the parent company seeks to restore Wall Street's confidence in its stock following a poor 2001 showing